Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 4/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322543 | 1.00 | GRM4 (0.46) | GRM4HSP90AB1KDM4ERAB9AHPGD | |
| SCHEMBL13110216 | 0.90 | MAPK14 (0.44) | HSP90AB1KDM4ERAB9AHPGDSMN1; SMN2 | |
| SCHEMBL13110215 | 0.90 | HSP90AB1 (0.47) | HSP90AB1KDM4EHPGDALDH1A1LMNA | |
| SCHEMBL13110212 | 0.88 | HPGD (0.46) | KDM4ERAB9AHPGDSMN1; SMN2NPC1 | |
| SCHEMBL13110222 | 0.87 | MEN1 (0.41) | HSP90AB1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL13110217 | 0.86 | MAPT (0.43) | HPGDALDH1A1LMNANPSR1MAPT | |
| SCHEMBL13126247 | 0.85 | HSP90AB1 (0.42) | HSP90AB1KDM4ERAB9AHPGDSMN1; SMN2 | |
| SCHEMBL13110228 | 0.85 | HSP90AB1 (0.42) | HSP90AB1KDM4ERAB9AHPGDSMN1; SMN2 | |
| SCHEMBL27642800 | 0.84 | GRM4 (0.48) | GRM4HSP90AB1KDM4EHPGDALDH1A1 | |
| SCHEMBL13110229 | 0.84 | HSP90AB1 (0.43) | HSP90AB1KDM4ERAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675861-B1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS R&D LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1675861-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005021552-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS (CAMBRIDGE) LTD (GB) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120767-A1 | Pyrimidothiophene Compounds | ALK, HSP90AA1, HSP90AB1 | GRM4 4508/4885HSP90AB1 3/4885KDM4E 4373/4885 |
| US-20070043044-A1 | Pyrimidothiophene compounds | ALK, HSP90AA1, HSP90AB1 | GRM4 4499/4885HSP90AB1 3/4885KDM4E 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.